In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 1, 2001, Pages 25-33

  Connolly, Kevin ^a   Cho, Yun Hee ^a   Duan, Roxanne ^a   Fikes, James ^a   Gregorio, Theresa ^a   Lafleur, David W ^a   Okoye, Zebedee ^a   Salcedo, Theodora W ^a   Santiago, Gemma ^a   Ullrich, Stephen ^a   Wei, Ping ^a   Windle, Kathleen ^a   Wong, Eling ^a   Yao, Xiao Tao ^a   Zhang, Ya Qin ^a   Zheng, Grace ^a   Moore, Paul A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TR 6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL VIABILITY; DRUG EFFECT; HEPATITIS; HUMAN; HUMAN CELL; LIGAND BINDING; LIVER CIRRHOSIS; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; FEMALE; HEPATOCYTES; HT29 CELLS; HUMANS; IMMUNOGLOBULIN G; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PEPTIDES; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B;

EID: 0034967223     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Death receptors: Signaling and modulation
2. Graft versus host disease associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell mediated FasL function but not porforin
3. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes
4. Fas-FasL interactions: A common pathogenic mechanism in organ-specific autoimmunity
5. Multiple sclerosis: Fas signaling in oligodendrocyte cell death
6. CD95-induced apoptosis in human liver disease
7. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival
8. Requirements for Fas for the development of autoimmune diabetes in non-obese diabetic mice
9. Disparate roles for TNF and Fas ligand in concanavalin A-induced hepatitis
10. Apoptosis and viral hepatitis
11. Chronic neutropenia mediated by Fas ligand
12. Fas and FasL in the homeostatic regulation of immune responses
13. Therapeutic opportunities from the pharmacological manipulation of the Fas system
14. Apoptosis by death factor
15. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice
16. Apoptosis and alcoholic liver disease
17. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpes virus entry mediator
18. Lethal effect of the anti-Fas antibody in mice
19. Dysregulation of apoptosis as a mechanism of liver disease: An overview
20. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
21. Expression of lymphotoxins and their receptor-Fc fusion proteins by baculovirus
22. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure
23. Conversion of membrane-bound Fas ligand to its soluble form is associated with down regulation of its pro-apoptotic activity and loss of liver toxicity
24. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in noninsulin dependent diabetes mellitus
25. Molecular cloning and expression of the Fas ligand: A novel member of the TNF family
26. Involvement of Fas/FasL system-mediated apoptosis in the development of concanavalin A-induced hepatitis
27. Fas ligand in human serum
28. Apoptosis and the pathogenesis and treatment of disease
29. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis
30. Role of Fas-mediated cell death in the regulation of immune responses
31. Fas and FasL deficient mice are resistant to induction of autoimmune encephalomyelitis
32. Cell death induced by the Fas/FasL pathway and its role in pathology
33. Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury
34. Mouse islet cell lysis mediated by IL-1 induced Fas
35. A newly identified member of the tumor necrosis factor superfamily (TR6) suppresses LIGHT-mediated apoptosis
36. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer